Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurisco Pharmaceutical CoSHSE:605116 -1.88%78 PB Ratio is 2.80 as of Jul. 25, 2026, which is 38% below its 10-year median of 4.55. GuruFocus rates SHSE:605116 with a GF Score™ of 78/100 and a GF Value™ of ¥28.92 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Aurisco Pharmaceutical Co ranks worse than 50.12% on this metric.
Aurisco Pharmaceutical Co Ltd stock PB Ratio (=2.9) is close to 10-year low of 2.82.
The historical rank and industry rank for Aurisco Pharmaceutical Co's PB Ratio or its related term are showing as below:
SHSE:605116'
s PB Ratio Range Over the Past 10 Years
Min: 2.8 Med: 4.55 Max: 7.21
Current: 2.8
During the past 10 years, Aurisco Pharmaceutical Co's highest PB Ratio was 7.21. The lowest was 2.80. And the median was 4.55.
SHSE:605116's PB Ratio is ranked worse than 50.12% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs SHSE:605116: 2.80
During the past 12 months, Aurisco Pharmaceutical Co's average Book Value Per Share Growth Rate was 11.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.10% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Aurisco Pharmaceutical Co was 22.00% per year. The lowest was 11.90% per year. And the median was 16.60% per year.
Back to Basics: PB Ratio
Aurisco Pharmaceutical Co (SHSE:605116) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aurisco Pharmaceutical Co PB Ratio Related Terms
Aurisco Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:605116 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Aurisco Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurisco Pharmaceutical Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aurisco Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aurisco Pharmaceutical Co (SHSE:605116) has a PB Ratio of 2.80 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aurisco Pharmaceutical Co and its competitors. This is 38% below median its historical median of 4.55. Over the past decade, Aurisco Pharmaceutical Co's PB Ratio has ranged from 2.80 to 7.21. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #616 out of 1229 companies in the Biotechnology industry, placing it in the top 50.1%.
Is Aurisco Pharmaceutical Co's PB Ratio too high?
Aurisco Pharmaceutical Co's current PB Ratio of 2.80 is 38% below median its 10-year median of 4.55. Over the past 10 years, this metric has ranged from a low of 2.80 to a high of 7.21. The Biotechnology industry median PB Ratio is 2.79. Aurisco Pharmaceutical Co's value of 2.80 is 0.4% above this industry median. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #616 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #616 out of 1229 companies for PB Ratio. This places Aurisco Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 2.79. Aurisco Pharmaceutical Co's value of 2.80 is 0.4% above this benchmark. Historically, Aurisco Pharmaceutical Co's own PB Ratio has ranged from 2.80 to 7.21 over the past decade. While the company's 10-year median is 4.55 vs. the industry median of 2.79, Aurisco Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurisco Pharmaceutical Co's current PB Ratio of 2.80 is 0.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aurisco Pharmaceutical Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurisco Pharmaceutical Co's current PB Ratio is 2.80, which is 38% below median its own 10-year median of 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥28.92, compared to a current price of ¥18.74 — trading 35.2% below its estimated fair value. The current PB Ratio is 2.80, which is 38% below median its 10-year median of 4.55 and 0.4% above the Biotechnology industry median of 2.79. Aurisco Pharmaceutical Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current PB Ratio is 2.80 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.74 is trading 35.2% below its estimated GF Value™ of ¥28.92.
GuruFocus considers Aurisco Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:605116:
PB Ratio: 2.80 (38% below median its 10-year median of 4.55)
GF Value™: ¥28.92 vs. price of ¥18.74 (35.2% below fair value)
Industry Position: 0.4% above the Biotechnology median (#616 of 1229)
No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
78GF Score
Get the complete analysis for SHSE:605116
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605116 has been successfully added to your 
